According to Katapult, the 13 companies taking part in the fourth and final programme for the fund represent the “most technically advanced and commercially mature” group of startups to date, with an average valuation of €25m.
The fund will make pre-seed up to series A investments, also providing firms with strategic support and access to international networks to attract further investment.
Aerska develops RNA medicines for the treatment of neurological diseases such as Parkinson’s and Alzheimer’s, which affect millions of people worldwide.
Sustainability-linked bonds (SLBs) offer investors a way to align their investments with measurable environmental outcomes, while also serving as a test of both government policy credibility and environmental ambition, according to Ninety One.
After a tough start to the year, confidence has returned among impact founders and investors in Europe, a new report by Swedish venture capitalist Norrsken VC said.
The investment brings total assets under management to around $95m, which will be used to support SMEs in developing countries working in the fields of renewable energy and sustainable agriculture.
The funding will enable the company to scale and commercialise its cloud-linked device, which allows medical professionals to remotely monitor key patient indicators such as heart rate, respiratory rate, and oxygen saturation.
From now on you will receive our newsletter 3 times a week (Tue, Thu and Fri).
Free newsletter. Sign up now
Register your email address and receive our newsletter direct to your inbox.
Offering independent news and analysis about impact investing and sustainable finance.
For free.
